KeyBanc upgrades Rocket Lab stock rating on launch progress

KeyBanc upgraded Rocket Lab USA to Overweight from Sector Weight and set a $135 price target, implying about 40% upside from the current $102.39 share price. The firm highlighted 46% revenue growth over the last twelve months, approximately 90 successful Electron missions, and continued progress on the Neutron rocket, with the January testing anomaly fully resolved. The note is supportive for RKLB, while additional catalysts include Stifel’s $132 target, upcoming Nasdaq-100 inclusion effective June 22, 2026, and broader investor attention on the space sector.

Analysis

The real signal is not the rating change itself but the implied de-risking of Neutron and the shift from a one-product launch story to a platform story. That matters because the market has already been paying for a best-case launch cadence; what can still drive upside now is evidence that Rocket Lab can monetize adjacent infrastructure, not just execute on Electron. If Neutron stays on schedule, the stock can keep compounding on operating leverage, but the bar for further multiple expansion is now execution plus backlog conversion, not just “space enthusiasm.”

Second-order beneficiaries are the broader launch supply chain and any smallsat/defense names tied to reusable medium-lift capacity, because a credible Neutron path tightens the competitive window for legacy launch providers and raises the value of integrated satellite manufacturing. The Nasdaq-100 inclusion is also non-trivial for flows: passive buying can create a short, mechanical demand shock, but that effect is usually front-run and fades unless fundamentals keep improving. The bigger medium-term effect is improved liquidity and index-ownership stability, which lowers the cost of capital and can support follow-on issuance if management chooses to accelerate adjacent investments.

The contrarian risk is that the stock may already discount several years of flawless execution, especially after a huge run and with valuation screens still stretched. Any delay, even a modest one, in first launch timing or a test anomaly resurfacing would hit a name like this harder than the upside from another analyst upgrade, because the equity is trading more like a pre-profit platform option than a normal industrial. Also, if management starts signaling ambition around its own satellite constellation, investors may initially cheer the TAM expansion but then question capital intensity and dilution risk; that is a classic way to convert a premium narrative into a margin-compression story.

Key Decisions for Investors

• Long RKLB on pullbacks into index-inclusion flow: 2-8 week horizon, targeting the mid-teens upside on passive demand and sentiment continuation, with a tight stop if launch-timeline commentary slips.
• Buy RKLB Jan-2027 calls or call spreads: 6-18 month horizon, using the options market to express upside to Neutron execution while capping downside if the program is delayed.
• Pair trade: long RKLB / short a legacy launch or aerospace prime basket over 3-6 months, betting that credible medium-lift commercialization re-rates the disruptor faster than slower-growth incumbents.
• Take profits on momentum spikes: trim 20-30% of long exposure into sharp post-announcement rallies, because valuation leaves little room for a missed milestone or soft guidance.
• Watch for secondary offering risk: if management hints at funding satellite-constellation ambitions, reduce exposure unless the capital plan is paired with near-term revenue accretion.